Logo image of CTMX

CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

NASDAQ:CTMX - Nasdaq - US23284F1057 - Common Stock - Currency: USD

0.78  -0.04 (-4.42%)

Fundamental Rating

3

CTMX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. CTMX may be in some trouble as it scores bad on both profitability and health. CTMX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CTMX had positive earnings in the past year.
In the past year CTMX has reported a negative cash flow from operations.
In the past 5 years CTMX always reported negative net income.
In the past 5 years CTMX reported 4 times negative operating cash flow.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

CTMX's Return On Assets of 9.95% is amongst the best of the industry. CTMX outperforms 96.45% of its industry peers.
Looking at the Return On Invested Capital, with a value of 26.84%, CTMX belongs to the top of the industry, outperforming 99.64% of the companies in the same industry.
Industry RankSector Rank
ROA 9.95%
ROE N/A
ROIC 26.84%
ROA(3y)-24.16%
ROA(5y)-22.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K 15K 20K

1.3 Margins

CTMX has a Profit Margin of 10.92%. This is amongst the best in the industry. CTMX outperforms 95.38% of its industry peers.
With an excellent Operating Margin value of 5.30%, CTMX belongs to the best of the industry, outperforming 94.32% of the companies in the same industry.
Industry RankSector Rank
OM 5.3%
PM (TTM) 10.92%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

More info and screens

2

2. Health

2.1 Basic Checks

CTMX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CTMX has been increased compared to 1 year ago.
The number of shares outstanding for CTMX has been increased compared to 5 years ago.
CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -5.82, we must say that CTMX is in the distress zone and has some risk of bankruptcy.
CTMX has a Altman-Z score of -5.82. This is in the lower half of the industry: CTMX underperforms 65.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.82
ROIC/WACC2.84
WACC9.44%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

CTMX has a Current Ratio of 1.04. This is a normal value and indicates that CTMX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CTMX (1.04) is worse than 88.28% of its industry peers.
A Quick Ratio of 1.04 indicates that CTMX should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.04, CTMX is not doing good in the industry: 86.86% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.04
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

CTMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 136.96%, which is quite impressive.
The Revenue has grown by 67.59% in the past year. This is a very strong growth!
Measured over the past years, CTMX shows a quite strong growth in Revenue. The Revenue has been growing by 11.21% on average per year.
EPS 1Y (TTM)136.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)67.59%
Revenue growth 3Y0.27%
Revenue growth 5Y11.21%
Sales Q2Q%26.71%

3.2 Future

Based on estimates for the next years, CTMX will show a very negative growth in Earnings Per Share. The EPS will decrease by -87.96% on average per year.
Based on estimates for the next years, CTMX will show a decrease in Revenue. The Revenue will decrease by -5.92% on average per year.
EPS Next Y-118.59%
EPS Next 2Y-384.13%
EPS Next 3Y-233.99%
EPS Next 5Y-87.96%
Revenue Next Year27.18%
Revenue Next 2Y-10.69%
Revenue Next 3Y-29.38%
Revenue Next 5Y-5.92%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 4.59, the valuation of CTMX can be described as very cheap.
98.93% of the companies in the same industry are more expensive than CTMX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CTMX to the average of the S&P500 Index (29.63), we can say CTMX is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 4.59
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -15.64
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

CTMX's earnings are expected to decrease with -233.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-384.13%
EPS Next 3Y-233.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTMX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (2/21/2025, 8:11:15 PM)

0.78

-0.04 (-4.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners59.66%
Inst Owner Change-98.45%
Ins Owners1.99%
Ins Owner Change21.65%
Market Cap61.04M
Analysts80
Price Target4.78 (512.82%)
Short Float %5.94%
Short Ratio3.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.57%
Min EPS beat(2)45.28%
Max EPS beat(2)139.87%
EPS beat(4)4
Avg EPS beat(4)155.17%
Min EPS beat(4)45.28%
Max EPS beat(4)301.21%
EPS beat(8)7
Avg EPS beat(8)100.82%
EPS beat(12)8
Avg EPS beat(12)62.89%
EPS beat(16)11
Avg EPS beat(16)51.05%
Revenue beat(2)2
Avg Revenue beat(2)55.14%
Min Revenue beat(2)23.14%
Max Revenue beat(2)87.14%
Revenue beat(4)4
Avg Revenue beat(4)55.97%
Min Revenue beat(4)23.14%
Max Revenue beat(4)89.65%
Revenue beat(8)7
Avg Revenue beat(8)38.03%
Revenue beat(12)7
Avg Revenue beat(12)2.3%
Revenue beat(16)9
Avg Revenue beat(16)1.46%
PT rev (1m)-11.35%
PT rev (3m)-11.78%
EPS NQ rev (1m)4.53%
EPS NQ rev (3m)16.72%
EPS NY rev (1m)0%
EPS NY rev (3m)83.93%
Revenue NQ rev (1m)0.6%
Revenue NQ rev (3m)18.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.62%
Valuation
Industry RankSector Rank
PE 4.59
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -15.64
EPS(TTM)0.17
EY21.79%
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS1.62
BVpS-0.3
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.95%
ROE N/A
ROCE 33.97%
ROIC 26.84%
ROICexc N/A
ROICexgc N/A
OM 5.3%
PM (TTM) 10.92%
GM N/A
FCFM N/A
ROA(3y)-24.16%
ROA(5y)-22.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 25.68%
Cap/Sales 0.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.04
Altman-Z -5.82
F-Score5
WACC9.44%
ROIC/WACC2.84
Cap/Depr(3y)56.24%
Cap/Depr(5y)79.07%
Cap/Sales(3y)2.77%
Cap/Sales(5y)3.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-118.59%
EPS Next 2Y-384.13%
EPS Next 3Y-233.99%
EPS Next 5Y-87.96%
Revenue 1Y (TTM)67.59%
Revenue growth 3Y0.27%
Revenue growth 5Y11.21%
Sales Q2Q%26.71%
Revenue Next Year27.18%
Revenue Next 2Y-10.69%
Revenue Next 3Y-29.38%
Revenue Next 5Y-5.92%
EBIT growth 1Y119.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.23%
OCF growth 3YN/A
OCF growth 5YN/A